Evaluation of neutrophil-to-lymphocyte ratio in newly diagnosed patients receiving borte- zomib-based therapy for multiple myeloma

Zhou, Xin; Wang, Jing; Xia, Jun; Cheng, Feng; Mao, Jingjue; Zhu, Jianwei; Guo, Hongwei

doi:10.3233/cbm-170795

Cited by 11 publications

(14 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, it has been suggested that the NLR can be used to predict prognosis in patients with MM. It has been reported in previous publications that an elevated NLR was associated with shortened OS in MM patients (4)(5)(6)23). In our study, there was no relationship between the NLR and both mortality and OS in patients with MM.…”

Section: Discussioncontrasting

confidence: 48%

The Prognostic Significance of the Neutrophil-to-Lymphocyte Ratio in Patients with Multiple Myeloma: A Pilot Study

Medetalibeyoğlu¹,

Akyüz²,

Bayrakdar³

et al. 2020

JARHS

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 48%

The Prognostic Significance of the Neutrophil-to-Lymphocyte Ratio in Patients with Multiple Myeloma: A Pilot Study

Medetalibeyoğlu¹,

Akyüz²,

Bayrakdar³

et al. 2020

JARHS

View full text Add to dashboard Cite

“…However, Zhou et al [51] reported that a high NLR (> 2.95) was associated with poor OS in MM patients treated up-front with bortezomib-based regimens, but it was not an independent prognostic factor in this cohort. These results suggest that the efficacy of NLR as a predictor of outcome may differ depending on the therapeutic agent.…”

Section: Discussionmentioning

confidence: 57%

The Derived Neutrophil-to-Lymphocyte Ratio Is an Independent Prognostic Factor in Transplantation Ineligible Patients with Multiple Myeloma

Lee

Park

et al. 2018

Acta Haematol

View full text Add to dashboard Cite

Background: The neutrophil-to-lymphocyte ratio (NLR) is an independent prognostic marker in solid and hematological cancers. While the derived NLR (dNLR) was shown to be non-inferior to the NLR in large cohorts of patients with different cancer types, it has not been validated as a prognostic marker for multiple myeloma (MM) to date. Methods: Between May 22, 2011 and May 29, 2014, 176 patients with MM from 38 centers who were ineligible for autologous stem cell transplantation were analyzed. The dNLR was calculated using complete blood count differential data. The optimal dNLR cut-off value according to receiver operating characteristic analysis of overall survival (OS) was 1.51. All patients were treated with melphalan and prednisone combined with bortezomib. Results: The complete response rate was lower in the high dNLR group compared to the low dNLR group (7 vs. 26.1%, respectively; p = 0.0148); the corresponding 2-year OS rates were 72.2 and 84.7%, respectively (p = 0.0354). A high dNLR was an independent poor prognostic factor for OS (hazard ratio 2.217, 95% CI 1.015–4.842; p = 0.0458). Conclusion: The dNLR is a readily available and cheaply obtained parameter in clinical studies, and shows considerable potential as a new prognostic marker for transplantation-ineligible patients with MM.

show abstract

“…In hematological malignancies, Troppan et al reported that dNLR ≥1.8 was a significant factor for 5-year disease-free survival (DFS) in DLBCL patients treated with standard rituximab and CHOP (R-CHOP) regimen 15. Elevated NLR (≥2.95) was related to inferior OS in MM patients receiving induction therapy with bortezomib-based regimens 40. Our present study demonstrated that ENKTL patients who received first-line therapy with high dNLR (≥3.6) presented lower response (CR or PR) rate when compared to patients with lower dNLR.…”

Section: Discussionmentioning

confidence: 99%

<p>Prognostic significance of peripheral blood absolute lymphocyte count and derived neutrophil to lymphocyte ratio in patients with newly diagnosed extranodal natural killer/T-cell lymphoma</p>

Zhou

Sun

Zhao

et al. 2019

CMAR

View full text Add to dashboard Cite

Background: Accumulating evidence suggested that tumor microenvironment and host immune system played important roles in determining the clinical course and outcome of human malignancies. The derived neutrophil to lymphocyte ratio (dNLR) and absolute lymphocyte count (ALC) were demonstrated to act as a prognostic factor in several malignancies. Nevertheless, the prognostic significance of them in extranodal natural killer/T-cell lymphoma (ENKTL) patients has never been explored. Patients and methods: A total of 33 newly diagnosed patients with ENKTL were included in this study. Clinicopathological characteristics were collected and prognostic significance of dNLR and ALC were evaluated. Results: Elevated dNLR and low ALC were both associated with poor survival rates. Patients with dNLR ≥3.6 revealed significantly shorter overall survival (OS) ( P =0.001) and progression-free survival (PFS) ( P =0.008) than those with dNLR <3.6. Patients with ALC <0.8×10 9 /L had worse OS ( P =0.008) and PFS ( P <0.001) than those with ALC ≥0.8×10 9 /L. An independent significant association between low ALC and poor clinical outcome in multivariate analysis for OS (HR, 36.023; 95% CI, 2.438–532.243; P =0.009) as well as PFS (HR, 7.698; 95%CI, 1.573–37.679; P =0.012) was identified. Conclusion: In this study, we validated for the first time the prognostic value of dNLR and ALC in ENKTL patients. Elevated dNLR and low ALC were both associated with aggressive tumor process and poor survival.ALC value at diagnosis represented an independent favorable prognostic factor for the clinical outcome of ENKTL patients.

show abstract

Evaluation of neutrophil-to-lymphocyte ratio in newly diagnosed patients receiving borte- zomib-based therapy for multiple myeloma

Abstract: Elevated NLR was associated with poor OS in MM patients receiving induction therapy with bortezomib-based regimens, but it was not an independent prognostic factor in this patient cohort.

Cited by 11 publications

References 21 publications

The Prognostic Significance of the Neutrophil-to-Lymphocyte Ratio in Patients with Multiple Myeloma: A Pilot Study

The Prognostic Significance of the Neutrophil-to-Lymphocyte Ratio in Patients with Multiple Myeloma: A Pilot Study

The Derived Neutrophil-to-Lymphocyte Ratio Is an Independent Prognostic Factor in Transplantation Ineligible Patients with Multiple Myeloma

<p>Prognostic significance of peripheral blood absolute lymphocyte count and derived neutrophil to lymphocyte ratio in patients with newly diagnosed extranodal natural killer/T-cell lymphoma</p>

Contact Info

Product

Resources

About